- Jun 11, 2021SWK Holdings' Subsidiary, Enteris BioPharma, Receives $10 Million Milestone Payment from Cara TherapeuticsThird milestone payment related to the development of Oral KORSUVA™
- Jun 07, 2021
- May 17, 2021Conference Call and Live Audio Webcast Scheduled for Tuesday, May 18, 2021 at 10:00 a.m. ET
Corporate Updates YTD SWK has closed two financings totaling up to $14.0 million Enteris BioPharma subsidiary announced completion of manufacturing facility expansion and launch of CDMO business...
- May 17, 2021SWK Holdings and Carlson Capital L.P. Announce Board Changes, Formation of Strategic Review Committee and Update on Previously-Disclosed Non-Binding Proposal
The Board of Directors (the "Board") of SWK Holdings Corporation (Nasdaq: SWKH) (the "Company" or "SWK") and its controlling stockholder, funds affiliated with Carlson Capital, L.P. ("Carlson"),...
- May 03, 2021Enteris BioPharma Completes Expansion of Manufacturing Facility and Announces Launch of CDMO Business SegmentCDMO Business Driven by Custom Solutions from Bench to Market for the Development and Manufacture of Difficult to Formulate Drugs and Highly Potent Compounds